U.S. healthcare policy is undergoing rapid change, with wide-ranging consequences for biopharma strategy, pricing, and competitiveness. From government efforts to control drug costs to shifts in vaccine policy to PBM reform, manufacturers face a complex and evolving policy landscape. At the same time, evolving trade policies have created a climate of uncertainty for biopharma companies, making it difficult to manage supply chains and make long-term plans.
Watch this session for a breakdown of the policy developments that matter most for biopharma leaders—what’s changing, how it may impact the industry, and the strategies companies are deploying to adapt.
